search
Back to results

Cognitive Impairment in Pediatric Onset Multiple Sclerosis

Primary Purpose

Pediatric Onset Multiple Sclerosis, ADHD Predominantly Inattentive Type

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Attention Processing Training program (APT)
nonspecific computer training (n-ST)
Sponsored by
Pietro Iaffaldano
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pediatric Onset Multiple Sclerosis

Eligibility Criteria

undefined - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • POMS diagnosed according to the most recent diagnostic criteria;
  • age <18 years;
  • Expanded Disability Status Scale (EDSS) score ≤5.5;
  • impairment on at least 2/4 attention tests defined as scores <1.5 standard deviation (SD) of normative values;
  • ADHD patients with the subtype inattention;
  • ADHD diagnosis performed according the DSM-5 criteria and the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention- Deficit/Hyperactivity Disorder (MTA) - Swanson, Nolan, and Pelham IV Rating Scale (MTA-SNAP-IV), Conner's Parent Rating Scale Revised (CPRS-R), Conner's Teacher Rating Scale Revised (CTRS-R), Child Behavior Checklist (CBCL), Kiddie Schedule for Affective Disorder and Schizophrenia (K-SADS);
  • age <18 years;
  • impairment on at least 2/4 attention tests defined as scores <1.5 standard deviation (SD) of normative values;

Exclusion Criteria:

  • severe cognitive impairment (performance ≤2.0 SD of normative values);
  • severe visual loss (unable to read Times New Roman font 16 with the best correction);
  • major psychiatric illness;
  • alcohol or substance abuse;
  • education <5 years;
  • previous cognitive rehabilitation training;
  • ongoing relapse or steroid treatment during the 30 days preceding enrollment;
  • ADHD subtype hyperactivity;
  • previously exposure or treatment with any psychotropic drug.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Active Comparator

    Experimental

    Active Comparator

    Arm Label

    specific computer training (ST) - POMS

    nonspecific computer training (n-ST) - POMS

    specific computer training (ST) - ADHD

    nonspecific computer training (n-ST) - ADHD

    Arm Description

    Outcomes

    Primary Outcome Measures

    to evaluate the effect of the cognitive training on neuropsychological performances.
    A global score, defined Cognitive Impairment Index (CII), allowing the evaluation of changes in cognitive performances independently by the number of cognitive tests failed at the neuropsychological evaluation, will be obtained using the mean and SD from the normative values for each test.

    Secondary Outcome Measures

    Full Information

    First Posted
    June 15, 2017
    Last Updated
    June 15, 2017
    Sponsor
    Pietro Iaffaldano
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03190902
    Brief Title
    Cognitive Impairment in Pediatric Onset Multiple Sclerosis
    Official Title
    Cognitive Impairment in Pediatric Onset Multiple Sclerosis: Research of Biomarkers Predictive of Cognitive Impairment Progression
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    September 15, 2015 (undefined)
    Primary Completion Date
    April 30, 2016 (Actual)
    Study Completion Date
    April 30, 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Pietro Iaffaldano

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Computer-assisted rehabilitation of attention deficits in pediatric Multiple Sclerosis and ADHD patients recruited during the study "Cognitive impairment in Pediatric Onset Multiple Sclerosis: research of biomarkers predictive of cognitive impairment progression".
    Detailed Description
    The presence of cognitive deficits of varied intensity is characteristic of psychiatric disorders of childhood and adolescence such as Attention Deficit Hyperactivity Disorder (ADHD), but also of neurological pathologies such as pediatric onset multiple sclerosis (POMS). ADHD is one of the most common neurodevelopmental disorders characterized by pervasive patterns of inattention and/or impulsivity/hyperactivity and a range of cognitive dysfunctions that often persist into adulthood. POMS represent 5-10% of total MS population. Cognitive dysfunction is one of the most remarkable features of MS, and, particularly in POMS, the percentage of patients with at least a mild cognitive deficit ranges from 30 to 80%. The most affected cognitive domains in POMS are complex attention, information processing speed, executive functions, verbal and visual memory, reasoning and problem solving. The functional consequences of cognitive impairment can be particularly striking in children and adolescents since they occur during formative years in the academic career and may affect their social activities. Cognitive training, during the developmental age, when brain plasticity is at the highest expression, can induce a strengthening of the key brain networks implicated in POMS and ADHD. To date the efficacy of specific cognitive rehabilitation interventions has never been evaluated by a randomized controlled trials (RCTS) in POMS. Conversely, in the last years, several RCTs assessed the efficacy of cognitive training as a potential non-drug alternative treatment for ADHD disorder.Most of the cognitive trainings focused on the working memory or attention dysfunctions. Preliminary evidence suggests that cognitive remediation might be at least partially effective in the ADHD treatment. It is argued that cognitive training can reduce ADHD symptoms and improve functioning by targeting neuropsychological deficits thought to mediate ADHD pathophysiology. During the study project "Cognitive impairment in Pediatric Onset Multiple Sclerosis: research of biomarkers predictive of cognitive impairment progression", which is aimed to assess clinical, radiological and biological markers in pediatric subjects, POMS and ADHD patients will be recruited to assess the efficacy of a home-based computerized program for retraining attention dysfunction.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pediatric Onset Multiple Sclerosis, ADHD Predominantly Inattentive Type

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Single center, double blind, randomized clinical trial (RCT).
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    36 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    specific computer training (ST) - POMS
    Arm Type
    Experimental
    Arm Title
    nonspecific computer training (n-ST) - POMS
    Arm Type
    Active Comparator
    Arm Title
    specific computer training (ST) - ADHD
    Arm Type
    Experimental
    Arm Title
    nonspecific computer training (n-ST) - ADHD
    Arm Type
    Active Comparator
    Intervention Type
    Behavioral
    Intervention Name(s)
    Attention Processing Training program (APT)
    Intervention Type
    Behavioral
    Intervention Name(s)
    nonspecific computer training (n-ST)
    Primary Outcome Measure Information:
    Title
    to evaluate the effect of the cognitive training on neuropsychological performances.
    Description
    A global score, defined Cognitive Impairment Index (CII), allowing the evaluation of changes in cognitive performances independently by the number of cognitive tests failed at the neuropsychological evaluation, will be obtained using the mean and SD from the normative values for each test.
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Maximum Age & Unit of Time
    17 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: POMS diagnosed according to the most recent diagnostic criteria; age <18 years; Expanded Disability Status Scale (EDSS) score ≤5.5; impairment on at least 2/4 attention tests defined as scores <1.5 standard deviation (SD) of normative values; ADHD patients with the subtype inattention; ADHD diagnosis performed according the DSM-5 criteria and the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention- Deficit/Hyperactivity Disorder (MTA) - Swanson, Nolan, and Pelham IV Rating Scale (MTA-SNAP-IV), Conner's Parent Rating Scale Revised (CPRS-R), Conner's Teacher Rating Scale Revised (CTRS-R), Child Behavior Checklist (CBCL), Kiddie Schedule for Affective Disorder and Schizophrenia (K-SADS); age <18 years; impairment on at least 2/4 attention tests defined as scores <1.5 standard deviation (SD) of normative values; Exclusion Criteria: severe cognitive impairment (performance ≤2.0 SD of normative values); severe visual loss (unable to read Times New Roman font 16 with the best correction); major psychiatric illness; alcohol or substance abuse; education <5 years; previous cognitive rehabilitation training; ongoing relapse or steroid treatment during the 30 days preceding enrollment; ADHD subtype hyperactivity; previously exposure or treatment with any psychotropic drug.

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    29884144
    Citation
    Simone M, Viterbo RG, Margari L, Iaffaldano P. Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial. BMC Neurol. 2018 Jun 8;18(1):82. doi: 10.1186/s12883-018-1087-3.
    Results Reference
    derived

    Learn more about this trial

    Cognitive Impairment in Pediatric Onset Multiple Sclerosis

    We'll reach out to this number within 24 hrs